Study: Early Diagnosis and Management of Sclerosing Cholang
A Study was conducted to describe the characteristics and clinical course of children and young people with inflammatory bowel disease and sclerosing cholangitis (IBD-SC).

Retrospective analysis was done of clinical characteristics, management, and outcome of two separate cohorts of children and young people with IBD-SC managed in a tertiary pediatric gastroenterology center and in a tertiary pediatric hepatology center.

--82 pediatric patients with IBD-SC and a mean age at diagnosis of 11.9 ± 2.8 years were followed up for 6.8 ± 3.3 years.

--The most common type of IBD was ulcerative colitis (55%), followed by unclassified IBD (30%) and Crohn’s disease (15%).

--Autoimmune SC (ASC) was diagnosed in 72% and small duct SC in 28%. Complication-free and native liver survival were 96% and 100% at 5 years and 75% and 88% at 10 years after diagnosis, respectively.

--Patients in the gastroenterology center, who were diagnosed with liver disease at a shorter interval after IBD diagnosis compared with the hepatology center cohort (2.7±6.1 vs. 9.3±19.4 months) did not develop liver related complications during follow up.

In conclusion, these data implies that children with IBD-SC have better clinical outcomes than previously reported, particularly if they are detected early in their illness. When liver function problems are identified after IBD diagnosis in children, prompt evaluation for SC is recommended, including liver biopsy and biliary imaging.